In a filing to the exchanges Marksans Pharma Ltd announced that USFDA has granted approval to the Company for an Abbreviated New Drug Application (ANDA) for Loratadine Liquid Filled Capsules 10 mg.
The approved Loratadine Liquid Filled Capsules 10 mg is the therapeutical equivalent to the reference listed drug Claritin Liqui-Gels Capsules 10 mg of Bayer Healthcare, LLC.
The drug is an antihistamine that reduces the effects of natural chemical histamine in the body. Loratadine is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching and other symptoms for allergy.
Post filing of this new development, Marksans Pharma share price has surged up by almost 12 per cent and is currently trading at Rs 53.10. The share price opened at Rs 47.75 from a previous closing of Rs 47.70. The intraday high and the intraday low are Rs 53.85 and Rs 47.40 respectively. At 11.30 AM a total of 1,27,19,366 shares of the Company have exchanged hands on the counter NSE against the 20 days average volume of 37,75,453.
The 52 week high of the share is Rs 113.90 made on 28th December 2015 and Rs 33.50 made on 1st March 2016.
Important Fundamentals of Marksans Pharma Ltd
- Consolidated FY 15-16 PE Ratio - 24.87
- Consolidated Trailing PE Ratio - 40.75
- Standalone FY 15-16 PE Ratio - 27.31
- Standalone Trailing PE Ratio - 40.59
- Book Value - 10.79
- Market Cap (as of today) – Rs 1952.43 crores
According to Dynamic Levels researchers and stock analysts, Marksans Pharma is among the top 500 shares category for this quarter. It is one of the good scrip to invest in. The stock has strong financials and impressive fundamentals. For more details on the stock fundamentals and financials of the Company, please visit Marksans Pharma share price history.
No comments:
Post a Comment